Underlying Mechanisms and Treatment of Hypertension in Glomerular Diseases.

IF 3.9 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Hypertension Reports Pub Date : 2024-03-01 Epub Date: 2023-11-20 DOI:10.1007/s11906-023-01287-9

Sahar H Koubar, Alejandro Garcia-Rivera, Muner M B Mohamed, John E Hall, Michael E Hall, Mohamed Hassanein

{"title":"Underlying Mechanisms and Treatment of Hypertension in Glomerular Diseases.","authors":"Sahar H Koubar, Alejandro Garcia-Rivera, Muner M B Mohamed, John E Hall, Michael E Hall, Mohamed Hassanein","doi":"10.1007/s11906-023-01287-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to explore the underlying mechanisms that lead to hypertension in glomerular diseases and the advancements in treatment strategies and to provide clinicians with valuable insights into the pathophysiological mechanisms and evidence-based therapeutic approaches for managing hypertension in patients with glomerular diseases.Recent findings: In recent years, there have been remarkable advancements in our understanding of the immune and non-immune mechanisms that are involved in the pathogenesis of hypertension in glomerular diseases. Furthermore, this review will encompass the latest data on management strategies, including RAAS inhibition, endothelin receptor blockers, SGLT2 inhibitors, and immune-based therapies. Hypertension (HTN) and cardiovascular diseases are leading causes of mortality in glomerular diseases. The latter are intricately related with hypertension and share common pathophysiological mechanisms. Hypertension in glomerular disease represents a complex and multifaceted interplay between kidney dysfunction, immune-mediated, and non-immune-mediated pathology. Understanding the complex mechanisms involved in this relationship has evolved significantly over the years, shedding light on the pathophysiological processes underlying the development and progression of glomerular disease-associated HTN, and is crucial for developing effective therapeutic strategies and improving patients' outcomes.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":" ","pages":"119-130"},"PeriodicalIF":3.9000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-023-01287-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to explore the underlying mechanisms that lead to hypertension in glomerular diseases and the advancements in treatment strategies and to provide clinicians with valuable insights into the pathophysiological mechanisms and evidence-based therapeutic approaches for managing hypertension in patients with glomerular diseases.

Recent findings: In recent years, there have been remarkable advancements in our understanding of the immune and non-immune mechanisms that are involved in the pathogenesis of hypertension in glomerular diseases. Furthermore, this review will encompass the latest data on management strategies, including RAAS inhibition, endothelin receptor blockers, SGLT2 inhibitors, and immune-based therapies. Hypertension (HTN) and cardiovascular diseases are leading causes of mortality in glomerular diseases. The latter are intricately related with hypertension and share common pathophysiological mechanisms. Hypertension in glomerular disease represents a complex and multifaceted interplay between kidney dysfunction, immune-mediated, and non-immune-mediated pathology. Understanding the complex mechanisms involved in this relationship has evolved significantly over the years, shedding light on the pathophysiological processes underlying the development and progression of glomerular disease-associated HTN, and is crucial for developing effective therapeutic strategies and improving patients' outcomes.

Abstract Image

查看原文本刊更多论文

高血压在肾小球疾病中的潜在机制及治疗。

综述目的:本综述旨在探讨肾小球疾病高血压的发病机制和治疗策略的进展，为临床医生了解肾小球疾病高血压的病理生理机制和循证治疗方法提供有价值的见解。近年来，我们对肾小球疾病中高血压发病机制的免疫和非免疫机制的理解有了显著的进展。此外，本综述将包括最新的管理策略数据，包括RAAS抑制、内皮素受体阻滞剂、SGLT2抑制剂和基于免疫的治疗。高血压(HTN)和心血管疾病是肾小球疾病死亡的主要原因。后者与高血压有着复杂的关系，并具有共同的病理生理机制。肾小球疾病中的高血压代表了肾功能障碍、免疫介导和非免疫介导病理之间复杂和多方面的相互作用。多年来，对这种关系的复杂机制的理解已经发生了重大变化，揭示了肾小球疾病相关HTN发生和进展的病理生理过程，对于制定有效的治疗策略和改善患者预后至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.